Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that this cannabinoid combination did not improve objective sleep outcomes in the short term. Patients and clinicians should be cautious about assuming that cannabinoid products reliably improve sleep, as the measurable effects on sleep architecture may differ substantially from subjective perception. Larger controlled trials are needed before firm clinical recommendations can be made.
#9 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first objective neurophysiological data on how a standardized THC/CBD combination affects sleep architecture in clinically diagnosed insomnia patients, addressing a critical gap given widespread patient use of cannabis for sleep without rigorous characterization of its effects. High-density EEG assessment enables detection of specific sleep stage alterations and next-day cognitive impacts that standard polysomnography cannot capture, potentially informing whether cannabinoid-based interventions warrant further development as evidence-based sleep therapeutics. These findings are essential for establishing whether cannabis produces clinically meaningful sleep improvements or merely subjective effects while potentially compromising sleep quality or daytime function.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides valuable objective data on cannabinoid effects in insomnia using high-density EEG, yet several limitations warrant careful interpretation before clinical adoption. The small sample size (n=20), single-dose design, and lack of detail on study completion and adverse events in the abstract limit our ability to draw firm conclusions about efficacy or safety in routine practice. The specific THC:CBD ratio tested (10:200 mg) may not reflect what patients are actually using in the community, where dosing practices are highly variable and often empirically driven. Most importantly, we still lack adequate long-term safety data, particularly regarding tolerance development, next-day cognitive effects, and potential dependency with repeated use in insomnia patients. Clinically, while this research helps fill knowledge gaps about cannabinoid mechanisms in sleep, I would counsel patients seeking cannabis for insomnia to first exhaust evidence-based first-line treatments (cognitive behavioral therapy for insomnia, sleep hygiene optimization, and FDA-approved medications when indicated), and